SCHEMBL4767773

SCHEMBL4767773

COC(=O)c1ccc(N(Cc2cccc(Cl)c2Cl)S(C)(=O)=O)c(C)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.49
MAPT P10636 2/20 0.49
ALDH1A1 P00352 5/20 0.48
POLB P06746 1/20 0.47
MCOLN3 Q8TDD5 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.41
CYP1A2 P05177 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41
GAA P10253 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
CYP2C9 P11712 2/20 0.40
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767671 0.91 MAPT (0.51) LMNAMAPTALDH1A1POLBMCOLN3
SCHEMBL4777409 0.84 ALDH1A1 (0.51) LMNAMAPTALDH1A1POLBMCOLN3
SCHEMBL4771011 0.83 LMNA (0.49) LMNAMAPTALDH1A1POLBMCOLN3
SCHEMBL4777540 0.81 POLB (0.54) LMNAMAPTALDH1A1POLBMCOLN3
SCHEMBL4777497 0.76 MAPT (0.49) LMNAMAPTALDH1A1POLBSMN1; SMN2
SCHEMBL4768135 0.76 MAPT (0.49) LMNAMAPTALDH1A1POLBSMN1; SMN2
SCHEMBL4771125 0.76 MAPT (0.55) LMNAMAPTALDH1A1POLBSMN1; SMN2
SCHEMBL18460409 0.76 POLB (0.54) MAPTALDH1A1POLBMCOLN3SMN1; SMN2
SCHEMBL4777650 0.76 GAA (0.60) LMNAMAPTALDH1A1POLBSMN1; SMN2
SCHEMBL4776409 0.76 MAPT (0.48) LMNAMAPTALDH1A1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 LMNA 1022/4885MAPT 294/4885ALDH1A1 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.